Email updates

Keep up to date with the latest news and content from Genetic Vaccines and Therapy and BioMed Central.

Open Access Highly Accessed Review

DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?

Sarfraz Ahmad13, Paul Sweeney2, Gerald C Sullivan1 and Mark Tangney1*

Author Affiliations

1 Cork Cancer Research Centre, BioSciences Institute, University College Cork, Cork, Ireland

2 Department of Urology, Mercy University Hospital Cork, Cork, Ireland

3 Department of Urology, Ninewells Hospital Dundee, Dundee, UK

For all author emails, please log on.

Genetic Vaccines and Therapy 2012, 10:9  doi:10.1186/1479-0556-10-9

Published: 9 October 2012

Abstract

Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and cellular immunity. This immune activation has been proven effective in animal models and initial clinical trials are encouraging. However, to validate the role of DNA vaccination in currently available PCa management paradigms, strong clinical evidence is still lacking. This article provides an overview of the basic principles of DNA vaccines and aims to provide a summary of preclinical and clinical trials outlining the benefits of this immunotherapy in the management of PCa.